Answers are grounded in this paper and cite their sources.
Consensus perspective highlights the need for standardized performance metrics in clinical photoacoustic imaging, indicating quality assurance is critical to reliably validate disease biomarkers.
To the Editor — Photoacoustic imaging (PAI) is a rapidly emerging imaging modality that enables optical absorption contrast to be visualized at high spatial resolution across length scales ranging from single organelles to intact living animals. Over the last two decades, PAI has been widely applied in preclinical studies, where it has been used to map the distribution of endogenous chromophores, such as haemoglobin, melanin and lipids, in living animals. Building on these successes, PAI has now entered the clinical realm and a wealth of scientific publications has demonstrated its potential in aiding studies of cancer, Crohn’s disease and arthritis, as well as other medical conditions. While several commercial clinical instruments are now available, there is an urgent need for standardized methodology that enables accurate and reproducible comparisons of the performance of different instruments. This is required for quality assurance and control, as well as for technical validation of the precision and accuracy of PAI biomarkers. Fig. 1 Summary of the goals of the IPASC thematic areas. Full size image
No takes yet. Share an insight, caveat, or question.
Sarah E. Bohndiek (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: